Inclusion Criteria:

- Cytologic or histologic proof of pancreatic ductal carcinoma

- Life expectancy > 3 months

- Adequate organ and marrow function

Exclusion Criteria:

- Evidence of metastatic disease

- Pregnant or breast-feeding

- Tumors in the body or tail of the pancreas

- Serious concomitant systemic disorders such as significant cardiac or pulmonary
morbidity (e.g. congestive heart failure, symptomatic coronary artery disease and
cardiac arrhythmias not well controlled with medication) or myocardial infarction
within the last 12 months, ongoing infection as manifest by fever

- Prior chemotherapy or radiation for treatment of the patient's pancreatic tumor

- Diagnosis of other invasive carcinomas (except basal cell carcinomas/squamous cell
carcinoma of the skin) with the last 5 years. Carcinoma in-situ is allowed.

- Other serious uncontrolled medical conditions

- Lack of physical integrity of the upper gastrointestinal tract or malabsorption
syndrome

- Known, existing uncontrolled coagulopathy

- Prior systemic fluoropyrimidine therapy (unless given in an adjuvant setting and
completed at least 6 months earlier). Prior unanticipated severe reaction to
fluoropyrimidine therapy, or known hypersensitivity to 5-fluorouracil or known DPD
deficiency

- Participation in any investigational drug study within 4 weeks preceding the start of
study treatment

- History of uncontrolled seizures, central nervous system disorders, or psychiatric
disability

- Major surgery, excluding laparoscopy, within 4 weeks of the start of study treatment,
without complete recovery

- Currently taking cimetidine

- Receiving any other study agents

- History of allergic reactions attributed to compounds of similar chemical or biologic
composition to capecitabine and HCQ

- Already taking HCQ or chloroquine for other diagnosis

- History of Grade 3 or greater retinopathy or keratitis